Intrathecal opioid conversions

The importance of lipophilicity

Mike A. Royal, Dan L. Wiesemeyer, Vitaly Gordin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

An intrathecal opioid infusion using an implanted programmable pump is frequently used for controlling refractory pain. Morphine, which is the only opioid presently approved by the FDA for use in such pumps, occasionally fails to work or is not tolerated by the patient; therefore other opioids are considered for infusions. When switching from one drug to another, it is important to consider not only equianalgesic dose conversions, but also lipophilicity. We report on three cases that demonstrate the need to use only a fraction of the equianalgesic dose when shifting from lipophilic to nonlipophilic opioids in such infusions. The concept of equianalgesic dosing of opioids is a familiar one to pain specialists. With the increasingly frequent use of intrathecal infusions, pain specialists must be aware of the potential significance of lipophilicity when changing from one opioid to another. Cerebrospinal fluid drug retention time can be prolonged, thus creating the potential for unintended sedation or respiratory depression when switching from fentanyl or sufentanil (highly lipid soluble narcotics) to morphine or hydromorphone (poorly lipid soluble) if the equianalgesic conversion is used without consideration of lipophilicity. To our knowledge, no one has previously reported on these potential dangers. We report on three cases demonstrating the importance of lipid solubility in intrathecal narcotic infusions.

Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalNeuromodulation
Volume1
Issue number4
DOIs
StatePublished - Jan 1 1998

Fingerprint

Opioid Analgesics
Narcotics
Lipids
Morphine
Hydromorphone
Drug Substitution
Sufentanil
Pain
Intractable Pain
Fentanyl
Respiratory Insufficiency
Solubility
Cerebrospinal Fluid
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Royal, Mike A. ; Wiesemeyer, Dan L. ; Gordin, Vitaly. / Intrathecal opioid conversions : The importance of lipophilicity. In: Neuromodulation. 1998 ; Vol. 1, No. 4. pp. 195-197.
@article{18ff3c5f9e264ae7ab21a758940c42c9,
title = "Intrathecal opioid conversions: The importance of lipophilicity",
abstract = "An intrathecal opioid infusion using an implanted programmable pump is frequently used for controlling refractory pain. Morphine, which is the only opioid presently approved by the FDA for use in such pumps, occasionally fails to work or is not tolerated by the patient; therefore other opioids are considered for infusions. When switching from one drug to another, it is important to consider not only equianalgesic dose conversions, but also lipophilicity. We report on three cases that demonstrate the need to use only a fraction of the equianalgesic dose when shifting from lipophilic to nonlipophilic opioids in such infusions. The concept of equianalgesic dosing of opioids is a familiar one to pain specialists. With the increasingly frequent use of intrathecal infusions, pain specialists must be aware of the potential significance of lipophilicity when changing from one opioid to another. Cerebrospinal fluid drug retention time can be prolonged, thus creating the potential for unintended sedation or respiratory depression when switching from fentanyl or sufentanil (highly lipid soluble narcotics) to morphine or hydromorphone (poorly lipid soluble) if the equianalgesic conversion is used without consideration of lipophilicity. To our knowledge, no one has previously reported on these potential dangers. We report on three cases demonstrating the importance of lipid solubility in intrathecal narcotic infusions.",
author = "Royal, {Mike A.} and Wiesemeyer, {Dan L.} and Vitaly Gordin",
year = "1998",
month = "1",
day = "1",
doi = "10.1111/j.1525-1403.1998.tb00016.x",
language = "English (US)",
volume = "1",
pages = "195--197",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "4",

}

Intrathecal opioid conversions : The importance of lipophilicity. / Royal, Mike A.; Wiesemeyer, Dan L.; Gordin, Vitaly.

In: Neuromodulation, Vol. 1, No. 4, 01.01.1998, p. 195-197.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intrathecal opioid conversions

T2 - The importance of lipophilicity

AU - Royal, Mike A.

AU - Wiesemeyer, Dan L.

AU - Gordin, Vitaly

PY - 1998/1/1

Y1 - 1998/1/1

N2 - An intrathecal opioid infusion using an implanted programmable pump is frequently used for controlling refractory pain. Morphine, which is the only opioid presently approved by the FDA for use in such pumps, occasionally fails to work or is not tolerated by the patient; therefore other opioids are considered for infusions. When switching from one drug to another, it is important to consider not only equianalgesic dose conversions, but also lipophilicity. We report on three cases that demonstrate the need to use only a fraction of the equianalgesic dose when shifting from lipophilic to nonlipophilic opioids in such infusions. The concept of equianalgesic dosing of opioids is a familiar one to pain specialists. With the increasingly frequent use of intrathecal infusions, pain specialists must be aware of the potential significance of lipophilicity when changing from one opioid to another. Cerebrospinal fluid drug retention time can be prolonged, thus creating the potential for unintended sedation or respiratory depression when switching from fentanyl or sufentanil (highly lipid soluble narcotics) to morphine or hydromorphone (poorly lipid soluble) if the equianalgesic conversion is used without consideration of lipophilicity. To our knowledge, no one has previously reported on these potential dangers. We report on three cases demonstrating the importance of lipid solubility in intrathecal narcotic infusions.

AB - An intrathecal opioid infusion using an implanted programmable pump is frequently used for controlling refractory pain. Morphine, which is the only opioid presently approved by the FDA for use in such pumps, occasionally fails to work or is not tolerated by the patient; therefore other opioids are considered for infusions. When switching from one drug to another, it is important to consider not only equianalgesic dose conversions, but also lipophilicity. We report on three cases that demonstrate the need to use only a fraction of the equianalgesic dose when shifting from lipophilic to nonlipophilic opioids in such infusions. The concept of equianalgesic dosing of opioids is a familiar one to pain specialists. With the increasingly frequent use of intrathecal infusions, pain specialists must be aware of the potential significance of lipophilicity when changing from one opioid to another. Cerebrospinal fluid drug retention time can be prolonged, thus creating the potential for unintended sedation or respiratory depression when switching from fentanyl or sufentanil (highly lipid soluble narcotics) to morphine or hydromorphone (poorly lipid soluble) if the equianalgesic conversion is used without consideration of lipophilicity. To our knowledge, no one has previously reported on these potential dangers. We report on three cases demonstrating the importance of lipid solubility in intrathecal narcotic infusions.

UR - http://www.scopus.com/inward/record.url?scp=17144427780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144427780&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1403.1998.tb00016.x

DO - 10.1111/j.1525-1403.1998.tb00016.x

M3 - Article

VL - 1

SP - 195

EP - 197

JO - Neuromodulation

JF - Neuromodulation

SN - 1094-7159

IS - 4

ER -